Mode
Text Size
Log in / Sign up
N/A N=460 Randomized Single-blind Other

An Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia

Cognitive Impairment

Enrolled (actual)
460
Serious AEs
0.0%
Results posted
Nov 2021
Primary outcome: Primary: Number of Patients Readmitted Because of Drug Related Reasons — 40; 50 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Medication review (Other)
Age
Older Adult · 65+ yrs
Sex
All
Sponsor
Umeå University
Primary completion
Jun 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients Readmitted Because of Drug Related Reasons
40; 50
SECONDARY
Cost for Visits for Readmissions and to the Emergency Department Compared Between Patients in the Control Group and Intervention Group.
2340; 2630
SECONDARY
Number of Participants Institutionalized After Discharge, in Control Group and Intervention Group.
17; 24
SECONDARY
Frequency of Emergency Department Visits During the 6-month Follow-up.
190; 184
SECONDARY
Change in the Number of Participants With Potentially Inappropriate Medications, According to the Swedish National Board of Health and Welfare, at Admission and Discharge Between Intervention and Control Group
13; 5

Summary

The aim of this randomized controlled study is to investigate if medication reviews performed by a clinical pharmacist as part of a ward team can reduce drug related problems and reduce readmissions to hospital among elderly patients (≥65 years) with dementia and cognitive failure. Four hundred and sixty patients will be recruited and randomized to control (usual care) and intervention group (enhanced service in which a pharmacist is part of the health care team). Six months after the last patient of the 460 has been discharged the study will be closed. Data about the number of readmissions and visits to the emergency room will be collected during the six-month follow-up and also, the costs associated with each visit or admission. Time until institutionalization will be compared between intervention group and control group.

Eligibility Criteria

Inclusion Criteria

  • Patients with dementia or cognitive impairment
  • Patients ≥ 65 years

Exclusion Criteria

  • Patients previously admitted to the study wards during the study period
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01504672). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search